A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab in Combination With Ipilimumab in Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Entinostat (Primary) ; Nivolumab (Primary) ; Ipilimumab
- Indications Adenocarcinoma; Breast cancer; Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 16 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018.
- 03 Dec 2015 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2017 as reported by ClinicalTrials.gov record.